点击次数：

论文类型：期刊论文

第一作者：Fu Shuang

通讯作者：Zhang, SF (reprint author), Dalian Univ Technol, State Key Lab Fine Chem, Dalian, Peoples R China.; Zhang, SB (reprint author), Dalian Minzu Univ, Minist Educ, Key Lab Biotechnol & Bioresources Utilizat, Dalian, Peoples R China.

合写作者：Xu Xiaodong,Ma Yu,Zhang Shubiao,Zhang Shufen

发表时间：2018-01-01

发表刊物：Journal of drug targeting

收录刊物：SCIE、PubMed

卷号：27

期号：1

页面范围：1-11

ISSN号：1029-2330

关键字：RGD,cancer therapy,integrin αvβ3,non-viral vector,targeted gene delivery

摘要：Integrin alphavbeta3 is restrictedly expressed on angiogenic blood vessels and tumour cells. It plays a key role in angiogenesis for tumour growth and metastasis. RGD peptide can specifically recognise the integrin alphavbeta3, which serves as targeted molecular for anti-angiogenesis strategies. Therefore, the targeted delivery of therapeutics by RGD peptide-based non-viral vectors to tumour vasculature and tumour cells is recognised as a promising approach for treating cancer. In this review, we illustrate the interaction between RGD peptide and integrin alphavbeta3 from different perspectives. Meanwhile, four types of RGD peptide-based non-viral gene delivery vectors for cancer therapy, including RGD-based cationic polymers, lipids, peptides and hybrid systems, are summarised. The aim is to particularly highlight the enhanced therapeutic effects and specific targeting ability exhibited by these vectors for cancer gene therapy both in vitro and in vivo.